Our data suggest that changes in ABC transporter expression within developing hematopoietic cells can significantly influence the specific cytopenias that are experienced by patients receiving cancer therapies, which may help to explain why neutropenia is a dominant dose-limiting toxicity for AURK inhibitors. Here, ABCG2 is linked to neutropenia.